Two Clocks at Novo: 2032's Patent Cliff, This Year's Cash Flow

Novo Nordisk just got a big Wall Street sell call, and the stock fell. On September 11, Morgan Stanley cut the Danish drugmaker to a Sell rating, and shares slipped about 2% to roughly $43 — on top of a five-day slide near 9% and a year-to-date drop above 15%. It sounds like the worst kind of news: analyst survey shows market share bleeding to Eli Lilly, and the key patent about to fall. But read what the call is actually pricing, and two very different clocks come into view. One is five years away. The other is this year's cash flow.

The bear case is built for 2031 and 2032

Morgan Stanley's downgrade rests on three things: modest mid-term growth, a valuation it calls demanding, and a "large patent cliff" for semaglutide, the molecule behind Ozempic and Wegovy that the bank says will be about 75% of Novo's sales in 2026. Its U.S. exclusivity runs until roughly 2032, and 2031 in Europe — so this is a terminal-value argument about what happens at the end of the decade, not about next year's results. The bank's own survey of 200 U.S. primary-care doctors projects Novo losing market share to Eli Lilly's Zepbound, Mounjaro, and a 2027 oral entrant over the next 18 months. It kept its price target at about $40, roughly 7% below the current price.

All of that is real, and worth weighing. But it is not the same clock that the company's own reports have been running.

What the reported numbers say

While Morgan Stanley argues the mid-term looks weak, Novo has been raising, not cutting, its 2026 guidance all year. In February it guided adjusted sales and operating profit to fall between 5% and 13%; after the first quarter it narrowed that to a 4% to 12% decline; and after the second quarter it raised it again, to a decline of no more than 6%, effectively flat holding the top of the range. First-half adjusted sales were up 2% at constant exchange rates. The engine is obesity care: the new oral Wegovy pill, launched in January, passed three million prescriptions by June, with most new scripts going to people who had never taken a GLP-1 before — market expansion rather than cannibalization of the injectable. Novo still trails Lilly, which Novo itself estimates wins seven or eight of every ten new U.S. obesity prescriptions, but the category is growing fast enough that both can grow: IQVIA pegs the global obesity-drug market rising from $66 billion in 2025 to $92 billion this year and possibly past $100 billion later this decade.

The free-cash-flow bridge

The one financial number that makes this beaten-down story concrete is free cash flow. It was negative in 2024 — a year dominated by the expensive Catalent manufacturing deal — turned positive at DKK 28.3 billion in 2025, and Novo now guides to between DKK 35 billion and 45 billion for 2026. That is not pure demand: a big part of the jump is that an enormous capex build is peaking and set to ease, so some of the "growth" is a one-time budget effect rather than stronger operations. Be honest about that. At a market cap around $190 billion, the forward free-cash-flow multiple is not obviously cheap the way the trailing earnings multiple is — the stock sits near 10.6x trailing earnings with a dividend yield around 3%, after falling about a third from its 52-week high. The aggregate analyst stance is a flat Hold: skeptical, expectant of nothing. The market has already reset so far that even a raised outlook this quarter barely moved it.

What would prove the thesis wrong

The honest risk is concentration: one molecule carrying three-quarters of sales, with exclusivity ending in the biggest markets by 2032, price pressure from "most favored nation" deals and generic semaglutide entering India, China, Brazil and Turkey, and a Lilly lead in U.S. obesity scripts that is not shrinking. None of that is fantasy, and a low multiple by itself is not a reason to buy — a beaten-down stock can stay beaten down if the operating path, not just the sentiment, keeps deteriorating.

So pin the case to what would actually break it. The thesis is wrong if the Wegovy oral franchise structurally decelerates rather than just softening seasonally — Morgan Stanley itself flagged the pill's second-half slowdown as a "credible risk" worth watching. It is wrong if Lilly's share gains accelerate beyond what guidance already assumes, or if price and margin erosion comes in worse than the raised numbers bake in. It holds only if free cash flow lands at or above the DKK 35 billion to 45 billion range, if the oral franchise keeps compounding, and if growth outside the flagship molecule slowly reduces that 75% concentration before the wall arrives.

This is not excitement, and I can be wrong again. The bear case is not wrong about 2032. The question the evidence forces on you is whether today's $43 — a third off the high, under 11 times earnings, with cash flow inflecting upward — already pays for a patent cliff that is still five or six years away. That is the two clocks disagreeing, and it is exactly where an expectations-reset story is worth your attention rather than your reflex.